Search research articles
Contact Us
Filters
Showing results (81-90 of 111) with videos related to
Page
of 12
Sort By:
British Journal of Cancer
|
September 29, 2004
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours
M J A de Jonge, S Kaye, J Verweij, et al.
British Journal of Cancer
|
December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C Benson, J White, J De Bono, et al.
British Journal of Cancer
|
January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumours
K H Khan, T A Yap, A Ring, et al.
Clinical Sarcoma Research
|
August 11, 2017
Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series
R B Cohen-Hallaleh, H G Smith, R C Smith, et al.
Scientific Reports
|
October 12, 2019
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma
A T J Lee, W Chew, C P Wilding, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2004
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter, H Dumez, I Judson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
A Le Cesne, I Judson, D Crowther, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 19, 2018
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy
N Touati, P Schöffski, S Litière, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F Duffaud, S Sleijfer, S Litière, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 25, 2003
Uterine sarcoma: twenty-seven years of experience
L Livi, F Paiar, N Shah, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 111) with videos related to
Sort By:
Page
of 12
British Journal of Cancer
|
September 29, 2004
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours
M J A de Jonge, S Kaye, J Verweij, et al.
British Journal of Cancer
|
December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C Benson, J White, J De Bono, et al.
British Journal of Cancer
|
January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumours
K H Khan, T A Yap, A Ring, et al.
Clinical Sarcoma Research
|
August 11, 2017
Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series
R B Cohen-Hallaleh, H G Smith, R C Smith, et al.
Scientific Reports
|
October 12, 2019
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma
A T J Lee, W Chew, C P Wilding, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2004
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter, H Dumez, I Judson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
A Le Cesne, I Judson, D Crowther, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 19, 2018
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy
N Touati, P Schöffski, S Litière, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F Duffaud, S Sleijfer, S Litière, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 25, 2003
Uterine sarcoma: twenty-seven years of experience
L Livi, F Paiar, N Shah, et al.
Page
of 12